Review
British Journal of Pharmacology (2001) 134, 1137–1150; doi:10.1038/sj.bjp.0704365
COX-2 and cancer: a new approach to an old problem
Y S Bakhle1
1Leukocyte Biology, Division of Biomedical Sciences, Faculty of Medicine, Imperial College, London SW7 2AZ
Correspondence: YS Bakhle, Leukocyte Biology, Division of Biomedical Sciences, Faculty of Medicine, Imperial College, London SW7 2AZ. E-mail: y.bakhle@ic.ac.uk
Received 3 August 2001; Revised 28 August 2001; Accepted 4 September 2001.
Keywords:
Angiogenesis, APC, apoptosis, aspirin, breast, (cancer), carcinogenesis, chemoprevention, chemotherapy, colorectal, (cyclo-oxygenase), cytokines, epidemiology, FAP, HNPCC, lung, Min mouse, NSAID, PPAR, prostate, sulindac, thiazolidinedione
Abbreviations:
APC, adenomatous polyposis coli; bFGF, basic fibroblast growth factor; COX, cyclooxygenase; CRC, colorectal cancer; C2I, selective inhibitor of COX-2; EGF, epidermal growth factor; FAP, familial adenomatous polyposis; FOBT, faecal occult blood tests; 5-FU, 5-fluorouracil; HNPCC, hereditary non-polyposis colon cancer; IL, interleukin; LPS, bacterial lipopolysaccharide; Min, multiple intestinal neoplasia; MMR, mismatch repair; NF
B, nuclear factor kappa B; NSAID, non-steroid anti-inflammatory drug; PG, prostaglandin; PGI2, prostacyclin; 15dPGJ2, 15-deoxy-delta 12,14-PGJ2; PPAR, peroxisome proliferator-activated receptor; RXR, retinoic acid receptor; TNF
, tumour necrosis factor alpha; TxA2, thromboxane A2; TZD, thiazolidinedione
